Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Viking Therapeutics' VK2735: A Leading Contender in Obesity Treatment With Strong Performance and Safety Profile
Press Release: Viking Mergers & Acquisitions Announces Key Promotions in Florida Division, Showcasing Internal Growth-Focused Culture and Leadership
Viking Mergers & Acquisitions Announces Key Promotions in Florida Division, Showcasing Internal Growth-Focused Culture and Leadership
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards
Trump Nominates Marty Makary For FDA Commissioner
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
How Is The Market Feeling About Viking Therapeutics?
Viking Therapeutics Analyst Ratings
B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109
Viking Therapeutics: Strong Potential in Obesity and Type 2 Diabetes Market With Innovative VK2735 Program
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs